Emine Hatipoglu
Impact in
- Infectious Diseases top 5%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
Papers in
-
- Cancer Genomics and Diagnostics 5
- Oncology 9
- Cancer Immunotherapy and Biomarkers 6
- CAR-T cell therapy research 5
- Co-authors
- James Larkin (2 shared papers)Albert Ferro (1 shared paper)Paul H. Huang (1 shared paper)Robin Jones (3 shared papers)Lavinia Anne Spain (1 shared paper)Eugenie Younger (1 shared paper)Dianne Nicol (1 shared paper)Andrew Rowan (1 shared paper)
- Journals
- The Lancet (4 papers)The Lancet Infectious Diseases (2 papers)Nature Ecology & Evolution (2 papers)Cancer Cell (2 papers)Nature Cancer (1 paper)
- Partner nations
- United KingdomUnited StatesFinland
In The Last Decade
Emine Hatipoglu
21 papers receiving 2.1k citations
Emine Hatipoglu's Hit Papers
Peers
Comparison fields: 5 of 98
- Infectious Diseases 621
- Cancer Research 452
- Modeling and Simulation 99
- Oncology 359
- Pulmonary and Respiratory Medicine 425
Countries citing papers authored by Emine Hatipoglu
This map shows the geographic impact of Emine Hatipoglu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emine Hatipoglu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emine Hatipoglu more than expected).
Fields of papers citing papers by Emine Hatipoglu
This network shows the impact of papers produced by Emine Hatipoglu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emine Hatipoglu. The network helps show where Emine Hatipoglu may publish in the future.
Co-authors
The 25 scholars most cited alongside Emine Hatipoglu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 515 | |
| 2 | Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination Hit paper breakdown → | 2021 | 391 |
| 3 | 2011 | 231 | |
| 4 | 2021 | 187 | |
| 5 | 2019 | 156 | |
| 6 | 2020 | 155 | |
| 7 | 2021 | 91 | |
| 8 | 2020 | 73 | |
| 9 | 2022 | 72 | |
| 10 | 2021 | 65 | |
| 11 | 2010 | 59 | |
| 12 | 2021 | 51 | |
| 13 | 2021 | 44 | |
| 14 | 2020 | 13 | |
| 15 | 2024 | 5 | |
| 16 | 2019 | 5 | |
| 17 | 2015 | 5 | |
| 18 | 2023 | 5 | |
| 19 | 2013 | 4 | |
| 20 | 2025 | 2 |
About Emine Hatipoglu
Emine Hatipoglu is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Infectious Diseases and Modeling and Simulation, having authored 22 papers that have together received 2.1k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (6 papers), Cancer Immunotherapy and Biomarkers (6 papers), Renal cell carcinoma treatment (6 papers), Cancer Genomics and Diagnostics (5 papers), CAR-T cell therapy research (5 papers), COVID-19 Clinical Research Studies (4 papers), Renal and related cancers (3 papers) and Sarcoma Diagnosis and Treatment (2 papers). The work is most often cited by research in Infectious Diseases (621 citations), Cancer Research (452 citations), Modeling and Simulation (99 citations), Oncology (359 citations) and Pulmonary and Respiratory Medicine (425 citations). Emine Hatipoglu has collaborated with scholars based in United Kingdom, United States and Finland. Frequent co-authors include James Larkin, Albert Ferro, Paul H. Huang, Robin Jones, Lavinia Anne Spain, Eugenie Younger, Dianne Nicol, Andrew Rowan, Anton Emmanuel and Lyra Del Rosario. Their work appears in journals such as The Lancet, The Lancet Infectious Diseases, Nature Ecology & Evolution, Cancer Cell and Nature Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.